Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNS PharmaceuticalsFRA:BE50 35 3-1 Month Momentum % is N/A% as of Sep. 21, 2026. GuruFocus rates FRA:BE50 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, CNS Pharmaceuticals ranks better than 83.67% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), CNS Pharmaceuticals's 3-1 Month Momentum % is N/A%.
The industry rank for CNS Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
FRA:BE50's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: 0.44 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CNS Pharmaceuticals 3-1 Month Momentum % Related Terms
FRA:BE50 vs ALZN, SNGX, AIM: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, CNS Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CNS Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CNS Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNS Pharmaceuticals (FRA:BE50) has a 3-1 Month Momentum % of N/A% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CNS Pharmaceuticals and its competitors. According to the industry distribution chart, CNS Pharmaceuticals ranks #226 out of 1384 companies in the Biotechnology industry, placing it in the top 16.3%.
Is CNS Pharmaceuticals' 3-1 Month Momentum % too high?
CNS Pharmaceuticals' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, CNS Pharmaceuticals ranks #226 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CNS Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' 3-1 Month Momentum % compare to ALZN and SNGX?
According to the Biotechnology industry distribution chart, CNS Pharmaceuticals ranks #226 out of 1384 companies for 3-1 Month Momentum %. This places CNS Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.44, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CNS Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CNS Pharmaceuticals's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (FRA:BE50) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. CNS Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CNS Pharmaceuticals (FRA:BE50), the current 3-1 Month Momentum % is N/A% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
35GF Score
Get the complete analysis for FRA:BE50
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BE50 has been successfully added to your 
